A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers


This study will evaluate the safety, tolerability, and pharmacokinetics of BTRC4017A in participants with locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-expressing cancers.

Study Start Date

March, 05 2018

Estimated Completion Date

May 2024


  • Drug: BTRC4017A

Study ID

Genentech, Inc. -- GO40311



Trial ID


Study Type


Trial Phase

Phase 1

Enrollment Quota



Genentech, Inc.

Inclusion Criteria
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Life expectancy of at least 12 weeks
  • Adequate hematologic and end-organ function
  • Acute, clinically significant treatment-related toxicity from prior therapy must have resolved to Grade Left Ventricular Ejection Fraction (LVEF) >/=50% HER2-Expressing Breast Cancer-Specific Inclusion Criteria
  • Locally tested, Human Epidermal Growth Factor Receptor 2 (HER2)-expressing BC
  • Locally advanced or metastatic BC that has relapsed or is refractory to established therapies HER2-Expressing Gastric/Gastroesophageal (GEJ) Cancer-Specific Inclusion Criteria
  • Adenocarcinoma of the stomach or GEJ with inoperable locally advanced or recurrent and/or metastatic disease, not amenable to curative therapy
  • HER2-expressing tumor (primary tumor or metastasis) as assessed by local lab testing
  • HER2-positive gastric/GEJ cancer must have received prior trastuzumab, cisplatin (or carboplatin or oxaliplatin or investigational platinum agent) and 5-fluorouracil (5-FU)/capecitabine HER2-Positive Solid Tumor Specific Inclusion Criteria
  • HER2-positive tumor (primary tumor or metastasis) as assessed by local (non-central) laboratory testing
  • Locally advanced, recurrent, or metastatic incurable malignancy that has progressed after at least one available standard therapy
  • or for whom standard therapy has proven to be ineffective or intolerable, or is considered inappropriate or for whom a clinical trial of an investigational agent is a recognized standard of care or for whom a clinical trial of an investigational agent is considered an acceptable treatment option Exclusion Criteria
  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 140 days after the last dose of BTRC4017A
  • Significant cardiopulmonary dysfunction
  • Known clinically significant liver disease
  • Positive for acute or chronic Hepatitis B virus (HBV) infection
  • Acute or chronic Hepatitis C virus (HCV) infection
  • Human Immunodeficiency Virus (HIV) seropositivity
  • Poorly controlled Type 2 diabetes mellitus
  • History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias
  • Current treatment with medications that are well known to prolong the Q-wave/T-wave (QT) interval
  • Known clinically significant liver disease
  • Primary central nervous system (CNS) malignancy, untreated CNS metastases, or active CNS metastases (progressing or requiring corticosteroids for symptomatic control)
  • Leptomeningeal disease
  • Spinal cord compression that has not definitively treated with surgery and/or radiation
  • History of autoimmune disease
  • Prior allogeneic stem cell or solid organ transplantation
  • Gender



    18 Years and older

    Accepts Healthy Volunteers


    Study Locations and Contact Information (4)

    Study Location Distance Name Phone Email
    Yale University - New Haven, Connecticut 118.9 miles None None None
    Memorial Sloan Kettering Cancer Center - New York, New York 187.1 miles None None None
    Sarah Cannon Research Institute - Nashville, Tennessee 942.8 miles None None None
    MD Anderson Cancer Center - Houston, Texas 1,609.9 miles None None None

    ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.